Reproductive Genetics
The Missing Half of NIPT
2026-07-23
NIPT is no longer defined by sequencing alone. The next phase depends on trustworthy interpretation, patient-specific reporting, and scalable informatics that clinicians can actually use.
Precision Oncology • Reproductive Genomics • Health-Tech
Dr. Rehan Mujeeb Faridi
Ph.D., HCLD/CC (ABB)
Molecular Geneticist | Clinical Consultant | Health Tech Innovator
I am a molecular geneticist and high-complexity clinical laboratory director with expertise spanning precision oncology, reproductive genomics, laboratory accreditation, and digital health innovation. Through my work in research, clinical and tech spaces, I have brought together scientific rigor, regulatory standards, and cutting-edge informatics to transform patient care and laboratory efficiency.
23+ peer-reviewed papers
Oncology • Immunogenetics
High Complexity Lab Director
Molecular Diagnostics
Expertise
Over a decade of cultivating depth across diverse specialties that reinforce one another.
Clinical Genomics & Lab Leadership
Designing, validating, and directing high-complexity NGS programs in hematologic and solid tumours, CGP, and liquid biopsy.
NK Cells & Immunogenetics
Advanced KIR–HLA/NK-cell biology applied to transplantation, immune dysregulation, and population immunogenomics.
Reproductive Genomics
Maternal–fetal immunology, NIPT/NIPTRix pipelines, pregnancy-loss genomics, and mosaicism detection.
Health-Tech & Laboratory Software
Architecting secure LIMS, portals, document systems, and analytics for regulated clinical laboratories.
Regulatory Alignment & Accreditation
CAP, CPSA, ADHICS, and DOH-aligned validation, quality management, and audit-ready documentation.
Infectious Disease Genomics & Metagenomics
High-throughput SARS-CoV-2 workflows. Collaborative works in clinical metagenomics and viral sequencing pipelines.
My Take
Where I think out loud about the ideas I chase across the lab, literature, and the code. And sometimes, life. Not peer reviewed.
Laboratory Software
The invisible Half of a Clinical Laboratory
2026-06-16
How a first-in-province NGS launch, a clinical accreditation, and a pile of spreadsheets led me to build SHELF.
Precision Oncology
The Long Tail of Actionable Cancer
2026-05-14
The Evolution and Impact of Comprehensive Genomic Profiling (CGP) on Cancer
Precision Oncology
A Practical Primer on Clinical Variant Interpretation
2025-11-21
This primer walks through the evolution of clinical variant interpretation—from the early days of ambiguous terminology to the modern era of consensus guidelines—and contrasts germline and somatic frameworks while outlining best practices and future directions in precision oncology.
Featured Publications
A rotating pick of peer-reviewed favorites.
NK Cell Alloreactivity and Post-HCT Outcomes
PLOS ONE • 2016
Citations: 27
A 284-patient cohort study exploring donor and recipient KIR genotypes and post-HCT outcomes.
0 views
ReadImpact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation
Cytotherapy • 2021
Citations: 7
A transplant-outcome study assessing whether FLT3-ITD and NPM1 mutations retain their prognostic value in AML patients treated with allogeneic hematopoietic cell transplantation.
0 views
ReadNK Cell Dysfunction in Severe COVID-19
Blood Advances • 2020
Citations: 124
A translational immunology study analyzing NK-cell counts, cytolytic function, and cytokine signatures in hospitalized patients with severe COVID-19.
0 views
ReadDonor IL-10 Genotype and GVHD Protection
International Journal of Molecular Sciences • 2022
Citations: 4
A cohort-based immunogenetic study evaluating donor cytokine gene variants and their impact on acute GVHD outcomes following allogeneic HCT.
0 views
Read